Evidence map›Paper›PMID 21867552›Full record

ArticleMalaria journal2011

Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites.

Mahamadou Diakite, Eric A Achidi, Olivia Achonduh, Rachel Craik, Abdoulaye A Djimde, Marie-Solange B Evehe, Angie Green, Christina Hubbart, Muntasir Ibrahim, Anna Jeffreys and 12 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 7 countries.

Mahamadou DiakiteMalaria Research and Training Centre, Faculty of Medicine, Pharmacy and Odontostomatology, University of Bamako, Mali. mdiakite@icermali.org
Eric A Achidi
Olivia Achonduh
Rachel Craik
Abdoulaye A Djimde
Marie-Solange B Evehe
Angie Green
Christina Hubbart
Muntasir Ibrahim
Anna Jeffreys
Baldip K Khan
Francis Kimani
Dominic P Kwiatkowski
Wilfred F Mbacham
Sabah Omar Jezan
Jean Bosco Ouedraogo
Kirk Rockett
Kate Rowlands
Nawal Tagelsir
Mamadou M Tekete
Issaka Zongo
Lisa C Ranford-Cartwright
University of Oxford · GBCentre for Human Genetics · GBUniversité de Yaoundé I · CMUniversity of Bamako · MLInstitut de Recherche en Sciences de la Santé · BFKenya Medical Research Institute · KEFederal Ministry of Health · SDInternational Atomic Energy Agency · ATUniversity of Buea · CMUniversity of Glasgow · GBUniversity of Khartoum · SD

Funding

Medical Research Council G0600718Medical Research Council G19/9Wellcome Trust 075491/Z/04Wellcome Trust 090532
6 · The paper itself

Abstract

backgroundResistance to anti-malarial drugs is a widespread problem for control programmes for this devastating disease. Molecular tests are available for many anti-malarial drugs and are useful tools for the surveillance of drug resistance. However, the correlation of treatment outcome and molecular tests with particular parasite markers is not perfect, due in part to individuals who are able to clear genotypically drug-resistant parasites. This study aimed to identify molecular markers in the human genome that correlate with the clearance of malaria parasites after drug treatment, despite the drug resistance profile of the protozoan as predicted by molecular approaches.

methods3721 samples from five African countries, which were known to contain genotypically drug resistant parasites, were analysed. These parasites were collected from patients who subsequently failed to clear their infection following drug treatment, as expected, but also from patients who successfully cleared their infections with drug-resistant parasites. 67 human polymorphisms (SNPs) on 17 chromosomes were analysed using Sequenom's mass spectrometry iPLEX gold platform, to identify regions of the human genome, which contribute to enhanced clearance of drug resistant parasites.

resultsAn analysis of all data from the five countries revealed significant associations between the phenotype of ability to clear drug-resistant Plasmodium falciparum infection and human immune response loci common to all populations. Overall, three SNPs showed a significant association with clearance of drug-resistant parasites with odds ratios of 0.76 for SNP rs2706384 (95% CI 0.71-0.92, P = 0.005), 0.66 for SNP rs1805015 (95% CI 0.45-0.97, P = 0.03), and 0.67 for SNP rs1128127 (95% CI 0.45-0.99, P = 0.05), after adjustment for possible confounding factors. The first two SNPs (rs2706384 and rs1805015) are within loci involved in pro-inflammatory (interferon-gamma) and anti-inflammatory (IL-4) cytokine responses. The third locus encodes a protein involved in the degradation of misfolded proteins within the endoplasmic reticulum, and its role, if any, in the clearance phenotype is unclear.

conclusionsThe study showed significant association of three loci in the human genome with the ability of parasite to clear drug-resistant P. falciparum in samples taken from five countries distributed across sub-Saharan Africa. Both SNP rs2706384 and SNP1805015 have previously been reported to be associated with risk of malaria infection in African populations. The loci are involved in the Th1/Th2 balance, and the association of SNPs within these genes suggests a key role for antibody in the clearance of drug-resistant parasites. It is possible that patients able to clear drug-resistant infections have an enhanced ability to control parasite growth.

Indexed as

Drug ResistancePolymorphism, Single NucleotideAdolescentAfricaAntimalarialsChildChild, PreschoolFemaleGenomicsHumansMalaria, FalciparumMaleMass SpectrometryPlasmodium falciparumAntimalarials

Identifiers

PMID21867552
PMCPMC3177816
OpenAlexW2116516937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.